Obesity & weight management
Tirzepatide may increase risk of disproportionate muscle loss vs. semaglutide
Clinical takeaway: In this early, not‑yet‑peer‑reviewed analysis, tirzepatide was associated with a signal for greater lean mass depletion relative to total weight loss compared with semaglutide. Clinicians may consider closer monitoring of lean body mass and functional status and reinforce resistance exercise and adequate protein intake early—especially in patients with baseline musculoskeletal pain or limited mobility.
As GLP‑1–based therapies deliver unprecedented weight reduction, clinicians are increasingly focused on whether that weight loss preserves lean tissue and physical function. A large new real‑world analysis suggests that this balance may differ between agents.
In a pre‑print study conducted by nference, a health‑analytics company, researchers analyzed EHR‑linked body‑composition data from 670,422 first‑episode GLP‑1RA users in routine care, including 456,742 treated with semaglutide and 213,680 with tirzepatide. Among 7,965 patients with paired pre‑ and post‑treatment body‑composition measurements, outcomes were assessed over 12 months using a digital phenotyping pipeline.
Across all measured time points, tirzepatide was associated with significantly greater relative lean body mass (LBM) loss than semaglutide. Excess LBM loss with tirzepatide was 1.1% at 3 months, 1.5% at 6 months, 1.3% at 9 months, and 2.0% at 12 months, suggesting lean tissue loss beyond what would be expected from greater weight loss alone.
A high‑risk “depletive GLP‑1 metabotype”—defined as >20% total body weight loss with >5% LBM loss—occurred more often with tirzepatide than semaglutide (10.3% vs. 6.7%; P<0.001). By contrast, a “lean‑preserving” response pattern was numerically but not significantly more common with semaglutide.
Higher drug dose and longer exposure were associated with progressively greater lean mass loss in both groups. Baseline musculoskeletal pain (e.g., knee pain, cervicalgia) and reduced exercise tolerance emerged as the strongest predictors of excessive LBM loss, pointing to a particular vulnerability among patients with limited mobility.
As the authors note, greater weight‑loss potency “does not necessarily translate into more favorable body‑composition outcomes,” highlighting muscle preservation as a key emerging consideration in obesity pharmacotherapy.
Source: Murugadoss K, et al. (2026, April 13). medRxiv. Greater lean‑body‑mass decline with tirzepatide than semaglutide in routine care, revealed by body‑composition digital phenotyping